Theodor Junginger1, Ursula Goenner, Mirjam Hitzler, Tong T Trinh, Achim Heintz, Daniel Wollschlaeger, Maria Blettner. 1. 1 Department of General and Abdominal Surgery, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany 2 Department of General, Visceral, and Vascular Surgery, Catholic Hospital Mainz, Mainz, Germany 3 Department of Heart, Chest, and Vascular Surgery, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany 4 Institute of Medical Biostatistics, Epidemiology, and Informatics, University Medical Centre, Johannes Gutenberg-University, Mainz, Germany.
Abstract
BACKGROUND: Transanal endoscopic microsurgery is superior to other methods of local excision of rectal cancer, but few studies report long-term follow-up data. OBJECTIVE: This study investigated the use of transanal endoscopic microsurgery alone as curative and compromise therapy based on long-term disease recurrence and mortality. DESIGN: This was a retrospective review of prospectively collected data. SETTINGS: The study was conducted at a tertiary care university medical center. PATIENTS: The study included 133 patients treated between 1985 and 2007. There were 3 groups, including transanal endoscopic microsurgery in curative intent (low-risk rectal carcinoma, including pT1, G1/2, L0, and LX with clear margins and a minimal distance between tumor and resection margin of >1 mm (N = 64) or clear margins only (N = 18 ))) and as compromise therapy (high-risk or incompletely resected rectal carcinoma; N = 51). MAIN OUTCOME MEASURES: Log-rank tests were used to compare overall and cancer-specific survival. RESULTS: The median follow-up time was 8.6 years (range, 0.2-25.1 years), and a total of 131 of 133 patients (98.5%) were followed >5 years or until death. The preoperative diagnosis of carcinoma was not associated with belonging into 1 of the 3 categories. In patients with low-risk completely (>1 mm) resected carcinoma, the 5- and 10-year local recurrence rates were 6.6% and 11.6%. In patients with high-risk or incompletely resected carcinoma, the rates were 32.5% and 35.0% (p = 0.006). The 5- and 10-year cancer-specific survival rates for low-risk patients were 98.0% and 91.0% and 84.3% and 74.3% for high-risk patients (p = 0.05). LIMITATIONS: The study was limited by its retrospective design and small subgroups. CONCLUSIONS: The high cancer-specific survival justifies transanal endoscopic microsurgery alone as curative treatment in low-risk rectal carcinoma. Complete resection is essential to lower the risk of local recurrence. The high local recurrence rate in patients with high-risk rectal carcinoma restricts the use of TEM alone as compromise therapy.
BACKGROUND: Transanal endoscopic microsurgery is superior to other methods of local excision of rectal cancer, but few studies report long-term follow-up data. OBJECTIVE: This study investigated the use of transanal endoscopic microsurgery alone as curative and compromise therapy based on long-term disease recurrence and mortality. DESIGN: This was a retrospective review of prospectively collected data. SETTINGS: The study was conducted at a tertiary care university medical center. PATIENTS: The study included 133 patients treated between 1985 and 2007. There were 3 groups, including transanal endoscopic microsurgery in curative intent (low-risk rectal carcinoma, including pT1, G1/2, L0, and LX with clear margins and a minimal distance between tumor and resection margin of >1 mm (N = 64) or clear margins only (N = 18 ))) and as compromise therapy (high-risk or incompletely resected rectal carcinoma; N = 51). MAIN OUTCOME MEASURES: Log-rank tests were used to compare overall and cancer-specific survival. RESULTS: The median follow-up time was 8.6 years (range, 0.2-25.1 years), and a total of 131 of 133 patients (98.5%) were followed >5 years or until death. The preoperative diagnosis of carcinoma was not associated with belonging into 1 of the 3 categories. In patients with low-risk completely (>1 mm) resected carcinoma, the 5- and 10-year local recurrence rates were 6.6% and 11.6%. In patients with high-risk or incompletely resected carcinoma, the rates were 32.5% and 35.0% (p = 0.006). The 5- and 10-year cancer-specific survival rates for low-risk patients were 98.0% and 91.0% and 84.3% and 74.3% for high-risk patients (p = 0.05). LIMITATIONS: The study was limited by its retrospective design and small subgroups. CONCLUSIONS: The high cancer-specific survival justifies transanal endoscopic microsurgery alone as curative treatment in low-risk rectal carcinoma. Complete resection is essential to lower the risk of local recurrence. The high local recurrence rate in patients with high-risk rectal carcinoma restricts the use of TEM alone as compromise therapy.
Authors: Yun-Geng Liu; Lei Zhang; Ji-Ran Huang; Jin-Rong Yi; Chuan-Fa Fang; Lai-Yang Xia; Hong-Quan Liu; Jian-Zhong Yi Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2017-09-20
Authors: Britt J P Hupkens; Monique Maas; Milou H Martens; Willem M L L G Deserno; Jeroen W A Leijtens; Patty J Nelemans; Frans C H Bakers; Doenja M J Lambregts; Geerard L Beets; Regina G H Beets-Tan Journal: Eur Radiol Date: 2017-06-30 Impact factor: 5.315
Authors: T Junginger; U Goenner; M Hitzler; T T Trinh; A Heintz; M Blettner; D Wollschlaeger Journal: Tech Coloproctol Date: 2017-03-01 Impact factor: 3.781
Authors: E González-Flores; F Losa; C Pericay; E Polo; S Roselló; M J Safont; R Vera; J Aparicio; M T Cano; C Fernández-Martos Journal: Clin Transl Oncol Date: 2016-11-30 Impact factor: 3.405